The carbohydrate switch between pathogenic and immunosuppressive antigen‐specific antibodies
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
IgG antibodies have one conserved N‐glycosylation site at Asn 297 in each of their constant heavy chain regions. These Fc glycans influence the overall structure and pro‐ or anti‐inflammatory effector functions of IgG antibodies. The biantennary core glycan structure, consisting of four N‐acetyl‐glucosamine (Glc NA c) and three mannose residues, can be further decorated with fucose, a bisecting Glc NA c and terminal galactose or galactose plus sialic acid. Non‐galactosylated (agalactosylated; G0) IgG antibodies have long been associated with pro‐inflammatory effector functions in autoimmune patients with rheumatoid arthritis (RA). In contrast, it has been shown that sialylated IgGs are responsible for anti‐inflammatory effects of intravenous immunoglobulin (IVIG; purified IgG from pooled human plasma), which is administered at high doses (2 g/kg) for the systemic treatment of autoimmune patients. It has become increasingly evident that pro‐inflammatory immune responses, such as autoimmune reactions, primarily induce antigen‐specific G0 IgGs, whereas tolerance induces immunosuppressive galactosylated and sialylated IgGs. Under physiological conditions, differentially glycosylated IgGs mediate their pro‐ or anti‐inflammatory effector functions obviously as immune complexes (IC) in an antigen‐specific manner. Therefore, antigen‐specific galactosylated and sialylated IgGs may be a promising therapeutic tool for re‐establishing tolerance against defined (self‐) antigens in autoimmune or allergic patients. Here, we summarize these findings and outline our viewpoint on the development and function of differentially glycosylated antigen‐specific IgG antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
BIRAC Consortium, Stahl, E. A., YEAR Consortium, Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y., Kurreeman, F. A. S., et al. (2010) · Nature Genetics · doi:10.1038/ng.582 · Cited by 1,253
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Malhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B. (1995) · Nature Medicine · doi:10.1038/nm0395-237 · Cited by 786
Agalactosyl glycoforms of IgG autoantibodies are pathogenic
Rademacher, T. W., Williams, P., & Dwek, R. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6123 · Cited by 253
Cited by
Mechanisms of Autoantibody-Induced Pathology
Ludwig, R. J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S. M., Komorowski, L., Luo, J., Cabral-Marques, O., Hammers, C. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00603 · Cited by 469
Emerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
“Of note, high-glycosylated antibodies can mediate anti-inflammatory effects independent of their specificity, as indicated by the therapeutic effects of intravenously administered immunoglobulins (142), although antigen-specific effects might be considerably stronger and require lower antibody concentrations (79, 81,…”
BackgroundKemmer, A., Bieber, K., Abadpour, A., Yu, X., Mitschker, N., Roth, S., Kauderer, C., Ludwig, R. J., Seeger, K., Köhl, J., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12804 · Cited by 3
Metadata
- Authors
- Collin, M., & Ehlers, M.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2013-06-28
- Volume
- 22
- Issue
- 8
- Pages
- 511-514
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W2032021173
- Cited by
- 73
- References
- 7
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.